Elamipretide has been tested in several human trials. A large Phase 3 primary mitochondrial myopathy trial did not meet its main treatment-effect endpoints, while Forzinity later received accelerated FDA approval for a narrow Barth syndrome population. That narrow approval does not establish broad mitochondrial or anti-ageing benefit.
Still uncertain: General anti-ageing, energy or performance benefits are not approved/established by the Barth-syndrome authorization.
By confirming your subscription, you agree to receive occasional WhichPeps Evidence Updates. Kit processes the signup and email delivery for WhichPeps. Privacy. Unsubscribe anytime.
What does the evidence mean in simple terms? table
What is it?
Mitochondria-targeted tetrapeptide
Entity type
Peptide
Research focus
Mitochondrial disease; Barth syndrome; broader mitochondrial research
Human evidence
Elamipretide has multiple human trials. In primary mitochondrial myopathy, small early studies showed signals but the 218-person Phase III MMPOWER-3 trial missed both co-primary endpoints. Barth syndrome follows a separate rare-disease evidence and regulatory pathway and should not be generalized to wellness use.
Regulatory status
Forzinity (elamipretide) received FDA accelerated approval for Barth syndrome patients ≥30 kg; this does not make generic SS-31 vials approved.
Main limitations
General anti-ageing, energy or performance benefits are not approved/established by the Barth-syndrome authorization.
Safety
Safety is product/indication-specific; accelerated approval means confirmatory evidence is still required.
Evidence reviewed
2026-09-18
i
Elamipretide has multiple human trials. In primary mitochondrial myopathy, small early studies showed signals but the 218-person Phase III MMPOWER-3 trial missed both co-primary endpoints. Barth syndrome follows a separate rare-disease evidence and regulatory pathway and should not be generalized to wellness use.
Outcome-level evidence
Evidence is not one score.
Each record below answers a narrower question about an outcome, population or context. Evidence status and the study finding are shown separately so strong evidence is not mistaken for a positive effect.
2021 · Randomized double-blind placebo-controlled crossover study · n=12
Blinded primary endpoints were not significantly different; longer open-label extension produced signals used in the broader rare-disease evidence package.
Safety is product/indication-specific; accelerated approval means confirmatory evidence is still required.
Injection-site reactions are common in trials. Evidence and risk vary by indication and formulation; approval for a narrow rare-disease context does not establish generic SS-31 use as safe or effective.
Technical details
Mechanism / biologyBinds mitochondrial cardiolipin and is intended to improve mitochondrial bioenergetic function.
Route / formulation boundaryGeneric SS31 research products are not equivalent to Forzinity and may differ in quality/formulation.
Identity / data-quality noteUse the canonical compound identity and studied formulation when interpreting evidence.
WhichPeps does not rely on a single headline study when the evidence base is broader. Primary research, registries, regulators and supporting records are kept distinct.
4structured study records
2outcome records
10linked source records
How to read these counts: they show evidence coverage, not evidence strength. One large, well-designed study can be more informative than several weak or indirect records.
Show supporting and discovery sources
Study pages above contain the records used for public evidence summaries. The links below include supporting, regulatory and literature-discovery sources; a registry or search result is not treated as proof of benefit.
Evidence rule: WhichPeps keeps human, animal, laboratory, regulatory and product/formulation evidence distinct. Common names help people find the page; they do not change the underlying scientific identity.
